Key Metrics
5.3
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.88
5-Year SI
5-year SI
- N/A 2-year SI
- 0.85 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q3
Oncology
SJR
- Q2 Oncology
- Q2 Hematology
- Q3 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.04
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
25%
4 to 6 months
62%
7 to 9 months
10%
Above 9 months
3%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Lymphoma
- Drug discovery
- Rituximab
- Diffuse large B-cell lymphoma
- Lymphoblastic Leukemia
- Lenalidomide
- Central nervous system
- Hematopoietic stem cell transplantation
- Overall survival
- Polycythemia vera
- Immunotherapy
- Poor prognosis
- Bendamustine
- Minimal residual disease
- Follicular lymphoma
- B-cell lymphoma
- Systematic review
- Seroconversion
- Progression-free survival
- Bortezomib
Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Hematological Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
PET2-Adapted Therapy in Patients With Advanced-Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater.
- 1 Jan 25
- Hematological oncology
-
Full paper
Title not available
- 1 Jan 25
- Hematological Oncology
-
Full paper
Hospital Palliative Care Team Consultations in Different Subgroups of Hematologic Malignancies.
- 1 Jan 25
- Hematological oncology
-
Full paper
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma.
- 1 Jan 25
- Hematological oncology
-
Full paper
In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.
- 1 Jan 25
- Hematological oncology
-
Full paper
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.
- 1 Jan 25
- Hematological oncology
Scite analysis
Powered by scite_
4.8k articles received 23.9k citations see all
- 1,146 Supporting
- 21,908 Mentioning
- 190 Contrasting
Editorial notices
- 3 Retractions
- 0 Withdrawals
- 1 Corrections
- 19 Errata
- 0 Expression of Concern
FAQs
How long has Hematological Oncology been actively publishing?
Hematological Oncology has been in operation since 1983 till date.
What is the publishing frequency of Hematological Oncology ?
Hematological Oncology published with a Quarterly frequency.
How many articles did Hematological Oncology publish last years ?
In 2023, Hematological Oncology published 841 articles.
What is the eISSN & pISSN for Hematological Oncology ?
For Hematological Oncology,eISSN is 1099-1069 and pISSN is0278-0232.
What is Citescore for Hematological Oncology ?
Citescore for Hematological Oncology is 5.3.
What is SNIP score for Hematological Oncology ?
SNIP score for Hematological Oncology is 1.04.
What is the SJR for Hematological Oncology ?
SJR for Hematological Oncology is Q3.
Who is the publisher of Hematological Oncology ?
WILEY is the publisher of Hematological Oncology.